var data={"title":"Allopurinol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Allopurinol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5588?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">see &quot;Allopurinol: Drug information&quot;</a> and <a href=\"topic.htm?path=allopurinol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Allopurinol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131745\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aloprim;</li>\n      <li>Zyloprim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131746\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alloprin;</li>\n      <li>Apo-Allopurinol;</li>\n      <li>JAMP-Allopurinol;</li>\n      <li>Mar-Allopurinol;</li>\n      <li>Novo-Purol;</li>\n      <li>Zyloprim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056400\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antigout Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Uric Acid Lowering Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056393\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">see &quot;Allopurinol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing presenting in multiple formats (mg/m<sup>2</sup>/dose, mg/m<sup>2</sup>/day, mg/kg/day, and a fixed mg dose); take extra precautions to ensure accuracy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperuricemia associated with chemotherapy management:</b> Maintain adequate hydration; begin allopurinol 1 to 2 days before initiation of induction chemotherapy; may continue for 3 to 7 days after chemotherapy (Coiffier 2008); daily doses &gt;300 mg should be administered in divided doses:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &lt;6 years: 150 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 6 to 10 years: 300 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;10 years and Adolescents: 600 to 800 mg daily for 2 to 3 days in 2 to 3 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Tumor lysis syndrome; intermediate-risk: Limited data available (Coiffier 2008): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Weight-directed dosing: 10 mg/kg/day divided every 8 hours; maximum daily dose: 800 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA-directed dosing: 50 to 100 mg/m<sup>2</sup>/<b>dose</b> every 8 hours; maximum daily dose: 300 mg/m<sup>2</sup>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: For patients unable to tolerate oral therapy (BSA-directed dosing):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Children and Adolescents: Initial: 200 mg/m<sup>2</sup>/day administered once daily or in equally divided doses at 6-, 8-, or 12-hour intervals</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: Tumor lysis syndrome; intermediate-risk: Limited data available: Infants, Children, and Adolescents: 200 to 400 mg/m<sup>2</sup>/day in 1 to 3 divided doses; maximum daily dose: 600 mg/<b>day</b> (Coiffier 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperuricemia associated with inborn errors of purine metabolism (Lesch-Nyhan syndrome):</b> Oral: Infants, Children, and Adolescents: Initial: 5 to 10 mg/kg/day; adjust dose to maintain a high-normal serum uric acid concentration and a urinary uric acid/creatinine ratio &lt;1; reported range: 3.7 to 9.7 mg/kg/day; usual maximum daily dose: 600 mg/<b>day</b> (Torres 2007; Torres 2007a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recurrent calcium oxalate renal stones (including glycogen storage disease):</b> Limited data available: Oral: Children and Adolescents: 4 to 10 mg/kg/day in divided doses 3 to 4 times daily; maximum daily dose: 300 mg/<b>day</b> (Copelvitch 2012; Santos-Victoriano 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Oral doses &gt;300 mg should be given in divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gout (chronic):</b> Oral: Initial: 100 mg once daily; increase at weekly intervals in increments of 100 mg/day as needed to achieve desired serum uric acid level. Usual dosage range: 200 to 300 mg/day in mild gout; 400 to 600 mg/day in moderate to severe tophaceous gout; maximum daily dose: 800 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Management of hyperuricemia associated with chemotherapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 600 to 800 mg daily in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 200 to 400 mg/m<sup>2</sup>/day (maximum: 600 mg/day) beginning 1 to 2 days before chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Intravenous daily dose can be given as a single infusion or in equally divided doses at 6-, 8-, or 12-hour intervals. A fluid intake sufficient to yield a daily urinary output of at least 2 L in adults is desirable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recurrent calcium oxalate stones:</b> Oral: 200 to 300 mg daily in single or divided doses; may adjust dose as needed to control hyperuricosuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Allopurinol and oxypurinol are dialyzable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Management of hyperuricemia associated with chemotherapy:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 30% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Intermittent hemodialysis: Administer 30% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis (PD): Administer 30% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Coiffier 2008: Dosage reduction of 50% is recommended in renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Oral, IV: Lower doses are required in renal impairment due to potential for accumulation of allopurinol and metabolites.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 20 mL/minute: 200 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 3 to 10 mL/minute: &le;100 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;3 mL/minute: &le;100 mg/dose at extended intervals</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b> Management of hyperuricemia associated with chemotherapy:</b> Oral, IV: Dosage reduction of 50% is recommended in renal impairment (Coiffier 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Gout:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initiate therapy with 50 to 100 mg daily, and gradually increase to a maintenance dose to achieve a serum uric acid level of &le;6 mg/dL (with close monitoring of serum uric acid levels and for hypersensitivity) (Dalbeth 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">In patients with stage 4 CKD or worse, initiate therapy at 50 mg/day, increasing the dose every 2 to 5 weeks to achieve desired uric acid levels of &le;6 mg/dL; doses &gt;300 mg/day are permitted so long as they are accompanied by appropriate patient education and monitoring for toxicity (eg, pruritus, rash, elevated hepatic transaminases). Some patients may require therapy targeted at a serum uric acid level &lt;5 mg/dL to control symptoms (ACR guidelines; Khanna 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Initial: 100 mg alternate days given postdialysis, increase cautiously to 300 mg based on response. If dialysis is on a daily basis, an additional 50% of the dose may be required postdialysis (Dalbeth 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131716\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aloprim: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyloprim: 100 mg, 300 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131701\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056405\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Fluid intake should be sufficient to yield neutral or slightly alkaline (preferably) urine and a daily urine output of at least 2 L in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer after meals with plenty of fluid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: The rate of infusion is dependent upon the volume of the infusion; infuse maximum single daily doses (600 mg/day) over &ge;30 minutes; whenever possible, therapy should be initiated at 12 to 24 hours (pediatric patients) <b>or</b> 24 to 48 hours (adults) before the start of chemotherapy known to cause tumor lysis (including adrenocorticosteroids) (Coiffier 2008). Intravenous daily therapy can be administered as a single infusion or in equally divided doses at 6-, 8-, or 12-hour intervals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131739\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder for injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Following preparation, intravenous solutions in NS or D5W should be stored at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not refrigerate reconstituted and/or diluted product. Must be administered within 10 hours of solution preparation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Store in a dry place. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056404\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Management of hyperuricemia associated with cancer treatment for leukemia, lymphoma, or solid tumor malignancies (FDA approved in pediatric patients [age not specified] and adults); management of primary or secondary gout (acute attack, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) (FDA approved in adults); management of recurrent calcium oxalate calculi (with uric acid excretion &gt;800 mg/day in men and &gt;750 mg/day in women) (FDA approved in adults); has also been used for treatment of hyperuricemia associated with inborn errors of purine metabolism (Lesch-Nyhan syndrome) and recurrent calcium oxalate calculi associated with glycogen storage disease </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Management of hyperuricemia associated with cancer treatment for leukemia, lymphoma, or solid tumor malignancies who cannot tolerate oral therapy (FDA approved in children and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131804\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allopurinol may be confused with Apresoline </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyloprim may be confused with zolpidem, ZORprin, Zovirax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131801\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Gout (acute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased liver enzymes, increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Ageusia, agranulocytosis, alopecia, angioedema, aplastic anemia, cataract, cholestatic jaundice, ecchymoses, eczematoid dermatitis, eosinophilia, exfoliative dermatitis, hepatic necrosis, hepatitis, hepatomegaly, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hyperbilirubinemia, hypersensitivity reaction, leukocytosis, leukopenia, lichen planus, macular retinitis, myopathy, necrotizing angiitis, nephritis, neuritis, neuropathy, onycholysis, pancreatitis, purpura, renal failure, skin granuloma (annulare), Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, toxic pustuloderma, uremia, vasculitis, vesicobullous dermatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131725\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity reaction to allopurinol or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Breast-feeding mothers and children (except those with cancer therapy-induced hyperuricemia or Lesch-Nyhan syndrome)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> While not an absolute contraindication, the American College of Rheumatology suggests avoiding the use of allopurinol in patients with the HLA-B*5801 genotype due to the increased risk of allopurinol hypersensitivity syndrome (AHS). The guidelines suggest HLA-B*5801 screening in patients with a high incidence of this genotype; this includes patients of Korean descent who have stage 3 or worse chronic kidney disease, as well as patients of Han Chinese or Thai descent regardless of kidney function (ACR guidelines [Khanna 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131705\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Bone marrow suppression has been reported in patients receiving allopurinol, most of whom received concomitant medications with a potential for hematologic toxicity. The onset occurs between 6 weeks to 6 years after allopurinol initiation. Varying degrees of bone marrow depression affecting one or more cell lines may occur (rare) in patients receiving allopurinol alone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May occasionally cause drowsiness; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Cases of hepatotoxicity (reversible) have been reported. Asymptomatic elevations of serum alkaline phosphatase or serum transaminases have been observed. Monitor for signs/symptoms of hepatotoxicity and evaluate liver function if they occur. Periodic liver function tests are recommended during the early stages of therapy in patients with preexisting hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Allopurinol has been associated with hypersensitivity reactions. In some instances a skin rash may be followed by more severe hypersensitivity reactions, including exfoliative, urticarial, and purpuric lesions, Stevens-Johnson syndrome, generalized vasculitis, and/or  hepatotoxicity (irreversible); some reactions have been fatal (rare). Discontinue at first sign of skin rash or other signs indicative of allergic reaction. Consider HLA-B*5801 testing in patients at a higher risk for allopurinol hypersensitivity syndrome (eg, Korean patients with stage 3 or worse CKD and Han Chinese and Thai descent regardless of renal function) prior to initiation of therapy (ACR guidelines [Khanna 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute gout attacks: Even when normal or subnormal serum uric acid levels have been attained, an increase in acute gout attacks has been reported during the early stages of allopurinol administration. When allopurinol is initiated, maintenance colchicine doses should generally be administered as prophylaxis. Additionally, it is recommended to initiate with a low allopurinol dose (100 mg daily) and increase at weekly intervals by 100 mg until a serum uric acid level of 6 mg/dL or less is attained (do not exceed the maximum recommended dose of 800 mg/day). In some cases, colchicine or anti-inflammatory agents may be required to suppress gouty attacks. After several months of therapy, attacks usually decrease in duration and severity. These episodes may be due to mobilization of urates from tissue deposits, causing fluctuations in the serum uric acid levels. Even with adequate allopurinol therapy, several months may be required to deplete the uric acid pool enough to achieve control of the acute attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Dose reductions are recommended in patients with renal impairment; monitor closely. Patients with reduced renal function receiving thiazide diuretics in combination with allopurinol may be at increased risk for hypersensitivity reactions. Some patients with pre-existing renal disease or poor urate clearance have shown a rise in BUN with allopurinol. Patients with renal impairment should be carefully monitored during the early stages of allopurinol treatment; reduce the dose or withdraw therapy if increased renal function abnormalities appear and persist. Renal failure associated with allopurinol has been observed in patients with hyperuricemia secondary to neoplastic diseases. Concurrent conditions including multiple myeloma and congestive myocardial disease were present among patients whose renal dysfunction increased after allopurinol was begun. Renal failure is also frequently associated with gouty nephropathy and rarely with hypersensitivity reactions associated with allopurinol. Albuminuria has been observed among patients who developed clinical gout following chronic glomerulonephritis and chronic pyelonephritis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant drug interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant medications: Concomitant use of allopurinol (at doses of 300 to 600 mg/day) with mercaptopurine or azathioprine will require a reduction in the mercaptopurine or azathioprine dose to approximately one-third to one-fourth of the usual dose. Subsequent dose adjustments may be necessary based on therapeutic response and toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not use to treat asymptomatic hyperuricemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hydration: Fluid intake sufficient to yield a daily urinary output of at least 2 L and maintenance of a neutral or (preferably) a slightly alkaline urine are desirable in order to avoid possible formation of xanthine calculi due to allopurinol therapy and to help prevent renal urate precipitation in patients receiving concomitant uricosuric agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298712\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131710\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13339&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amoxicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Amoxicillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ampicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Ampicillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the potential for allergic or hypersensitivity reactions to Allopurinol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Allopurinol.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Allopurinol may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. More specifically, allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides.  Management: Reduce the azathioprine dose to one third to one quarter of the usual dose if used concomitantly with allopurinol, and monitor closely for systemic toxicity (particularly hematologic toxicity, nausea, and vomiting).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacampicillin: Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Bacampicillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bendamustine: Allopurinol may enhance the adverse/toxic effect of Bendamustine. Specifically, the risk of severe skin reactions may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Allopurinol may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Allopurinol may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, bone marrow suppression. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Allopurinol may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Allopurinol may increase the serum concentration of Didanosine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Allopurinol may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: Allopurinol may increase the serum concentration of Mercaptopurine. Allopurinol may also promote formation of active thioguanine nucleotides.  Management: Reduce the mercaptopurine dose to one third to one quarter of the usual dose if used with allopurinol, and monitor closely for systemic toxicity. US labeling for mercaptopurine oral suspension (Purixan brand) recommends avoiding allopurinol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: Allopurinol may enhance the adverse/toxic effect of Pegloticase. Specifically, Allopurinol may blunt increases in serum urate that would signal an increased risk of anaphylaxis and infusion reactions. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: Allopurinol may diminish the therapeutic effect of Tegafur. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Allopurinol may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Allopurinol may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131712\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131728\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. Allopurinol crosses the placenta (Torrance 2009). An increased risk of adverse fetal events has not been observed (limited data) (Hoeltzenbein 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056399\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, serum uric acid levels every 2 to 5 weeks during dose titration until desired level is achieved and every 6 months thereafter (ACR guidelines [Khanna 2012]), liver function tests (periodically in patients with preexisting hepatic disease), renal function (BUN, serum creatinine or creatinine clearance (periodically), prothrombin time [periodically in patients receiving warfarin]); consider HLA-B*5801 testing prior to initiation of therapy in patients at a higher risk for allopurinol hypersensitivity syndrome (ACR guidelines [Khanna 2012]). Monitor hydration status, for signs and symptoms of hypersensitivity, hepatotoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056403\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Uric Acid Normal Values</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Age</b></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Normal Serum Concentration</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 3 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.8 to 5 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 6 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.2 to 4.7 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7 to 9 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 5 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 11 years</p>\n            <p style=\"text-indent:0em;\">Male</p>\n            <p style=\"text-indent:0em;\">Female</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\"></p>\n            <p style=\"text-indent:0em;\">2.3 to 5.4 mg/dL</p>\n            <p style=\"text-indent:0em;\">3 to 4.7 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 13 years: Male</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.7 to 6.7 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14 to 15 years: Male</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.4 to 7.8 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 15 years: Female</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 5.8 mg/dL</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16 to 19 years</p>\n            <p style=\"text-indent:0em;\">Male</p>\n            <p style=\"text-indent:0em;\">Female</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 8.6 mg/dL</p>\n            <p style=\"text-indent:0em;\">3 to 5.9 mg/dL</p></td></tr></tbody></table>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: 3.4 to 7 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: 2.4 to 6 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target: &le;6 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">In adults, values &gt;7 mg/dL are sometimes arbitrarily regarded as hyperuricemia, but there is no sharp line between normals on the one hand, and the serum uric acid of those with clinical gout. Normal ranges cannot be adjusted for purine ingestion, but high purine diet increases uric acid. Uric acid may be increased with body size, exercise, and stress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131704\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid. Allopurinol is metabolized to oxypurinol which is also an inhibitor of xanthine oxidase; allopurinol acts on purine catabolism, reducing the production of uric acid without disrupting the biosynthesis of vital purines.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131724\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gout: Decrease in serum and urine uric acid: 2 to 3 days; peak effect: 1 week or longer; normal serum urate levels achieved typically within 1 to 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer therapy-induced hyperuricemia: Median time to plasma uric acid control: 27 hours (Cortes 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 90% from GI tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>ss</sub>: IV: 0.84 to 0.87 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly oxidized to active metabolites, primarily oxypurinol </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~49% to 53% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: ~1 to 2 hours; Oxypurinol: ~15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: Allopurinol: 1.5 hours; Oxypurinol: 4.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (76% as oxypurinol, 12% as unchanged drug); feces (~20%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131723\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 20 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg; or a 1:4 mixture of cherry syrup concentrate and simple syrup, NF. Crush eight 300 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo;. Stable for 60 days refrigerated or at room temperature (Allen 1996; Nahata 2004).</p>\n    <div class=\"reference\">Allen LV Jr and Erickson MA 3rd, &quot;Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,&quot; <i>Am J Health Syst Pharm</i>, 1996, 53(16):1944-9.<span class=\"pubmed-id\">8862208</span></div>\r\n\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131727\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Allopurinol Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $4,680.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Aloprim Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $4,784.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Allopurinol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $48.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $92.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zyloprim Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $185.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $508.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131730\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acepurin (NL);</li>\n      <li>Adenock (JP);</li>\n      <li>AL (PH);</li>\n      <li>Alinol (TH);</li>\n      <li>Allo (CO, ZW);</li>\n      <li>Allo-Puren (DE);</li>\n      <li>Allogut (TR);</li>\n      <li>Allohexal (NZ);</li>\n      <li>Allonol (LK);</li>\n      <li>Allopin (TH);</li>\n      <li>Allopsel (VN);</li>\n      <li>Allopur (CH, NO);</li>\n      <li>Allopurinol-ratiopharm (LU);</li>\n      <li>Alloric (TH);</li>\n      <li>Alloril (IL);</li>\n      <li>Allorin (AU);</li>\n      <li>Allosig (AU);</li>\n      <li>Allozym (JP);</li>\n      <li>Allpargin (LU);</li>\n      <li>Allurase (PH);</li>\n      <li>Allurit (IT);</li>\n      <li>Alopron (BM, BS, GY, JM, MT, SR, TR, TT);</li>\n      <li>Alopur (IE);</li>\n      <li>Alopurinol (HR);</li>\n      <li>Aloric (BD);</li>\n      <li>Alositol (JP);</li>\n      <li>Alpurase (PH);</li>\n      <li>Alpuric (LU);</li>\n      <li>Alpurin (PH);</li>\n      <li>Alunlan (TW);</li>\n      <li>Aluric (LB);</li>\n      <li>Aluron (VE);</li>\n      <li>Anoprolin (JP);</li>\n      <li>Anzief (JP);</li>\n      <li>Ao Mai Bi Li (CN);</li>\n      <li>Aprinol (JP);</li>\n      <li>Apronal (TH);</li>\n      <li>Apurin (FI, GR);</li>\n      <li>Apurol (SA);</li>\n      <li>Atisuril (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Aurinol (PH);</li>\n      <li>Benoxuric (ID);</li>\n      <li>Bleminal (DE);</li>\n      <li>Caplenal (GB);</li>\n      <li>Cellidrin (DE);</li>\n      <li>Clint (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZM, ZW);</li>\n      <li>Decasurik (ID);</li>\n      <li>Dertrifort (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Etindrax (MX);</li>\n      <li>Foligan (DE);</li>\n      <li>Genozyl (MX);</li>\n      <li>Gichtex (AT);</li>\n      <li>Goutex (BD);</li>\n      <li>Goutilex (TW);</li>\n      <li>Hamarin (GB);</li>\n      <li>Huma-Purol (HU);</li>\n      <li>Isoric (ID);</li>\n      <li>Ketanrift (JP);</li>\n      <li>Ketobun-A (JP);</li>\n      <li>Litinol (VE);</li>\n      <li>Llanol (PH, VN);</li>\n      <li>Logout (LK);</li>\n      <li>Loric (SA);</li>\n      <li>Loric-100 (PH);</li>\n      <li>Loric-300 (PH);</li>\n      <li>Masaton (JP);</li>\n      <li>Mensil (PY);</li>\n      <li>Mephanol (AE, BF, BH, BJ, CH, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Miberic (VN);</li>\n      <li>Milurit (BG, CZ, HU, SK, VN);</li>\n      <li>Miniplanor (JP);</li>\n      <li>Neufan (JP);</li>\n      <li>Nilapur (ID);</li>\n      <li>Nipurol (VE);</li>\n      <li>No-Uric (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SY, YE);</li>\n      <li>Pritanol (ID);</li>\n      <li>Progout (AU, SG);</li>\n      <li>Proxuric (ID);</li>\n      <li>Puribel 300 (MX);</li>\n      <li>Puricemia (ID);</li>\n      <li>Puricos (ZA);</li>\n      <li>Purinol (AE, BD, IE, JO, MY, QA, RU, SA, ZW);</li>\n      <li>Remid (DE, PY);</li>\n      <li>Riball (JP);</li>\n      <li>Ridonra (TW);</li>\n      <li>Rinolic (ID);</li>\n      <li>Ripunin (TW);</li>\n      <li>Sadapron (VN);</li>\n      <li>Salterprim (ZA);</li>\n      <li>Sinoric (ID);</li>\n      <li>Takanarumin (JP);</li>\n      <li>Tipuric (IE);</li>\n      <li>Tonsaric (TW);</li>\n      <li>Trianol (PH);</li>\n      <li>Tylonic (ID);</li>\n      <li>Unizuric (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Unizuric 300 (MX);</li>\n      <li>Uric (JP);</li>\n      <li>Uricad (TH);</li>\n      <li>Uriconorm (CH);</li>\n      <li>Urinol (MY);</li>\n      <li>Urocuad (CO);</li>\n      <li>Urogquad (AR);</li>\n      <li>Uroquad (AE, BF, BJ, BM, BS, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, QA, SA, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);</li>\n      <li>Urosin (AT, DE, EC, LU);</li>\n      <li>Valeric (CN);</li>\n      <li>Xandase (TH);</li>\n      <li>Xanol (TH);</li>\n      <li>Xanurace (PH);</li>\n      <li>Xoric (BD);</li>\n      <li>Xylonol (TW);</li>\n      <li>Yi Da Tong (CN);</li>\n      <li>Zanuric (JO);</li>\n      <li>Zylapour (GR);</li>\n      <li>Zyloprim (AU, BB, BM, BS, CR, DO, GT, GY, HN, JM, MX, NI, PA, PH, PR, PY, SR, SV, TT);</li>\n      <li>Zyloric (AE, BE, BF, BH, BJ, BR, CH, CI, CL, CY, DE, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, HK, ID, IE, IN, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, OM, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TR, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Zyngot (PE);</li>\n      <li>Zyroric (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allopurinol tablets [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aloprim (allopurinol injection) [prescribing information]. Greenville, NC: : DSM Pharmaceuticals, Inc; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Appelbaum SJ, Mayersohn M, Dorr RT, et al. Allopurinol kinetics and bioavailability. ontravenous, oral and rectal administration. <i>Cancer Chemother Pharmacol</i>. 1982;8(1):93-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/7094203/pubmed\" target=\"_blank\" id=\"7094203\">7094203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. <i>J Clin Oncol</i>. 2008;26(16):2767-2778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/18509186/pubmed\" target=\"_blank\" id=\"18509186\">18509186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copelovitch L. Urolithiasis in children: medical approach. <i>Pediatr Clin North Am</i>. 2012;59(4):881-896.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/22857835/pubmed\" target=\"_blank\" id=\"22857835\">22857835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. <i>J Clin Oncol</i>. 2010;28(27):4207-4213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/20713865/pubmed\" target=\"_blank\" id=\"20713865\">20713865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. <i>Semin Dial</i>. 2007;20(5):391-395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/17897242/pubmed\" target=\"_blank\" id=\"17897242\">17897242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL and Nazareno AR, <i>2012 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>, 28th ed, St Louis, MO: Elsevier/Mosby, 2012, 58-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoeltzenbein M, Stieler K, Panse M, et al. Allopurinol use during pregnancy - outcome of 31 prospectively ascertained cases and a phenotype possibly indicative for teratogenicity. <i>PLoS One</i>. 2013;8(6):e66637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/23840514/pubmed\" target=\"_blank\" id=\"23840514\">23840514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamilli I, Gresser U. Allopurinol and oxypurinol in human breast milk. <i>Clin Investig</i>. 1993;71(2):161-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/8461629/pubmed\" target=\"_blank\" id=\"8461629\">8461629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1431-1446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/23024028/pubmed\" target=\"_blank\" id=\"23024028\">23024028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos-Victoriano M, Brouhard BH, Cunningham RJ 3rd. Renal stone disease in children. <i>Clin Pediatr (Phila)</i>. 1998;37(10):583-599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/9793728/pubmed\" target=\"_blank\" id=\"9793728\">9793728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torrance HL, Benders MJ, Derks JB, et al. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. <i>Pediatrics</i>. 2009;124(1):350-357.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/19564319/pubmed\" target=\"_blank\" id=\"19564319\">19564319</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. <i>Metabolism</i>. 2007. 56(9):1179-1186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/17697859/pubmed\" target=\"_blank\" id=\"17697859\">17697859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. <i>Orphanet J Rare Dis</i>. 2007;2:48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/allopurinol-pediatric-drug-information/abstract-text/18067674/pubmed\" target=\"_blank\" id=\"18067674\">18067674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zyloprim (allopurinol) [prescribing information]. Greenville, NC:DSM Pharmaceuticals, Inc; October 2003.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13339 Version 185.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F131745\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F131746\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056400\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056393\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F131716\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F131701\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056405\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F131739\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056404\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131804\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131801\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131725\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131705\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298712\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F131710\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131712\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131728\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056399\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1056403\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131704\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F131724\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F131723\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F131727\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F131730\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13339|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">Allopurinol: Drug information</a></li><li><a href=\"topic.htm?path=allopurinol-patient-drug-information\" class=\"drug drug_patient\">Allopurinol: Patient drug information</a></li></ul></div></div>","javascript":null}